New Indole–Benzimidazole Hybrids Built Through Optimized Multistep Synthesis

Chemists have reported the design and synthesis of a family of hybrid molecules that fuse three medicinally familiar building blocks into a single framework: an indole ring, a benzimidazole, and a piperazine carboxamide. The compounds, named indolylbenzimidazoles piperazinecarboxamide hybrids, or IBPCs, were assembled through a multistep route whose key step is a sodium bisulfite-mediated condensation–cyclization between an N-methyl-methoxyindole-3-aldehyde and substituted diaminobenzoic acids. Writing in Results in Chemistry, Pallalu Devendra Reddy and Sathananthan Kannadasan describe systematic optimization of every bond-forming step, gram-scale demonstration of the pivotal reaction, single-crystal X-ray confirmation of one representative structure, and a carefully qualified computational assessment of how the new molecules might engage disease-relevant proteins.

The rationale for combining indole and imidazole chemistry rests on their track record in drug development. Nitrogen-containing heterocycles form structural motifs in many clinically approved medicines, and indole-based drugs such as indomethacin, pindolol, and indapamide are in widespread clinical use. Imidazole derivatives, meanwhile, owe their utility to amphoteric character, hydrogen-bonding capacity, and a tendency to interact with biomolecular targets; FDA-approved examples include ketoconazole, clotrimazole, miconazole, and metronidazole. Scaffolds that merge the two pharmacophores have attracted growing interest because the combination can increase binding affinity, fine-tune physicochemical parameters, and open multiple positions for structural variation. Prior synthetic routes to such hybrids have relied on multicomponent reactions, transition-metal catalysis, and sustainable methods, but the authors note persistent drawbacks including poor scalability and sparse structure–activity relationship information for several analogue classes.

The synthetic campaign began with an attempt to cyclize N-methyl-5-methoxyindole-3-aldehyde with 3,4-diaminobenzoic acid under a reported procedure: equimolar reactants, triethylamine as base, dimethylformamide as solvent, 80–85 °C for 12 hours. No desired cyclized product formed, and the starting materials were recovered. A systematic screen of base, solvent, temperature, and time followed. Replacing triethylamine with sodium bicarbonate in DMF at 85 °C for 3 hours failed, as did raising the temperature to 100 °C for 12 hours, and the reaction in DMSO likewise returned only starting material. The breakthrough came with sodium bisulfite: in DMF at 85 °C the benzimidazole-fused indole product 3a appeared in 20% isolated yield.

Temperature proved decisive. Incremental elevation lifted the yield to 47% at 90 °C, 62% at 95 °C, and 76% at 100 °C over 12 hours. Solvent changes undermined the gains: acetone with either sodium bisulfite or sodium carbonate gave no detectable product, while acetonitrile delivered only 35% with bisulfite and 20% with carbonate. The optimal condition—sodium bisulfite in DMF at 100 °C for 12 hours—was then applied across substituted diamine derivatives, furnishing compounds 3a–f in very good to excellent yields. Crucially, the reaction was performed on gram scale for 3a with no loss of yield percentage, addressing one of the scalability concerns the authors identified in earlier literature on indole–imidazole hybrids.

Diversification proceeded through amide chemistry on the carboxylic acid handle. Coupling compound 3a with N-Boc-protected piperazine was deliberately designed to suppress competitive dimerization, since blocking one of the piperazine’s nucleophilic nitrogen sites favours monofunctionalized product. Initial attempts with the carbodiimide EDC·HCl and triethylamine in dichloromethane at 0–5 °C for 3 hours failed, and neither warming to 30 °C for 12 hours nor switching to DMF with triethylamine or potassium carbonate rescued the reaction; solubility limits of 3a in dichloromethane had already forced the solvent change. Switching to the uronium coupling reagent HBTU produced detectable product: 25% yield with triethylamine in DMF at 30 °C for 12 hours. Replacing the base with DIPEA improved matters, and progressive extension of reaction time raised the yield from 40% at 12 hours to 76% at 24 hours, establishing HBTU and DIPEA in DMF at 30 °C for 24 hours as the optimal amide-forming condition.

Deprotection of the Boc group then exposed a free piperazine nitrogen for a second amide coupling with aryl carboxylic acids, completing the IBPC library. Screening acid solutions for the deprotection step showed 3.3 M HCl in ethanol giving 60% yield, ethyl acetate 75%, and isopropyl acetate 80%, with 3.3 M HCl in 1,4-dioxane optimal at 90% yield of compound 6. The final amidation repeated the earlier pattern: EDC·HCl failed in every solvent–base combination tested, whereas HBTU with DIPEA in DMF improved with time, from 25% with triethylamine at 10 hours to 37%, 46%, 57%, and finally 76% after 36 hours at 30 °C. Acetone gave no product and acetonitrile only 10%. All structures were confirmed spectroscopically, and compound 8e was additionally validated by single-crystal X-ray diffraction under deposit CCDC 2404777.

With compounds 8a–8g in hand, sharing a common indolylbenzimidazole–piperazine framework but differing in terminal acyl groups of varied size, aromaticity, and heteroatom composition, the team turned to molecular docking. The computational protocol was unusually rigorous. Ligand structures were prepared as two neutral benzimidazole tautomers with three conformations each, and ligand-bound crystal structures were drawn from the Protein Data Bank, retaining target-specific cofactors and metals. Of 77 candidate structures, 56 met preparation and native-ligand pose-recovery criteria—eight antimalarial, 20 anticancer, 12 antidiabetic-related, and 12 anti-inflammatory targets plus four selectivity controls, spanning 55 distinct proteins. Docking used Uni-Dock 1.2.0 with Vina scoring, exhaustiveness 512, and up to 20 poses per run; three random seeds per conformation yielded 18 searches per compound–structure pair and 7,056 searches overall, with median scores calculated per tautomer from nine top-ranked poses.

The authors were explicit that docking scores indicate predicted preferences, not measured potency. IRAK4 offered a structural comparison through its co-crystallized benzimidazole ligand T20 (PDB 4RMZ), and reported anti-EGFR studies of benzimidazole–piperazine compounds provided a literature precedent, but the broader panel was selected principally by disease relevance and the availability of inhibitor-defined pockets. Among qualified reference-drug comparisons—the recovery criterion was met for 18 of 31 attempted, including 14 disease-associated targets—the lowest-scoring hybrid beat the reference drug for eight targets. Examples include 8f scoring −9.657 kcal/mol against pyrimethamine’s −8.912 at PfDHFR-TS, 8c at −10.570 versus erlotinib’s −6.902 at EGFR, and 8f at −12.637 versus roflumilast’s −9.222 at PDE4D, while imatinib and olaparib outscored the hybrids at ABL1 and PARP1. Unfavourable comparisons were reported alongside favourable ones.

External benchmarking exposed the limits of score ranking. Using 155 compounds from four separate ChEMBL biochemical assays, labelled before docking by activity thresholds, the protocol achieved ROC-AUC values of 0.864 for PfDHODH, 0.672 for PDE4D, 0.335 for EGFR, and 0.566 for AKR1B1. Only PfDHODH had a 95% bootstrap confidence interval wholly above chance (0.748–0.956), and even there all 25 benchmark actives scored more favourably than the highest-ranked hybrid, 8d, whose largest pose group held three of nine poses. Binding-mode consistency also diverged from score: at PfDHFR-TS, 8f’s stronger median score came with representative orientations 12.19 Å apart, whereas 8e’s single largest group contained all nine top-ranked poses despite a weaker −9.344 kcal/mol. The authors conclude that the results define target-dependent binding hypotheses for biological testing without establishing antimalarial, anticancer, antidiabetic, or anti-inflammatory activity.

ADMET predictions flagged shared development constraints. Six of the seven compounds exceeded 500 g/mol in molecular weight, and predicted aqueous log S values for the reference tautomer ranged from −5.72 to −4.43, indicating poor solubility. High intestinal absorption predictions were accompanied by high positive-class probabilities for hERG inhibition (0.83–0.97) and drug-induced liver injury (0.96–0.99)—model outputs the authors stress require experimental verification rather than measured absorption or toxicity. Taken together, the work delivers a scalable, broadly applicable synthetic platform for indole C-3-tethered benzimidazole–piperazine carboxamide hybrids, structurally validated and computationally profiled, positioned as a starting point for focused biological evaluation and terminal-group optimization that must balance pocket complementarity against solubility and safety liabilities.

Subject of Research: Multistep synthesis and computational evaluation of indolylbenzimidazole piperazinecarboxamide hybrid compounds

Article Title: Design and synthesis of unprecedented indolylbenzimidazoles piperazinecarboxamide (IBPCs) hybrids

Article References: Reddy, P. D., & Kannadasan, S. (2026). Design and synthesis of unprecedented indolylbenzimidazoles piperazinecarboxamide (IBPCs) hybrids. Results in Chemistry, 32, Article 104010. https://doi.org/10.1016/j.rechem.2026.104010

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.104010

Keywords: indole, benzimidazole, piperazine carboxamide, hybrid scaffolds, organic synthesis, reaction optimization, molecular docking, ADMET prediction, X-ray crystallography, medicinal chemistry, Uni-Dock, drug discovery